U.S., April 30 -- ClinicalTrials.gov registry received information related to the study (NCT06948539) titled 'To Evaluate the Tolerability and Pharmacokinetics of TQB2101 for Injection in Patients With Advanced Malignant Tumors' on April 17.
Brief Summary: To explore the tolerability and pharmacokinetics of TQB2101 for injection in subjects with advanced malignant tumors.
Study Start Date: April, 2025
Study Type: INTERVENTIONAL
Condition:
Breast Cancer
Lung Cancer
Colorectal Cancer
Intervention:
DRUG: TQB2101 for injection
TQB2101 for injection is a receptor tyrosine kinase-like orphan receptor-1 antibody drug conjugate.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmace...